JO
NKTR icon

John Overdeck’s Nektar Therapeutics NKTR Stock Holding History

John Overdeck’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-2,693
Closed -$1.97M – 3465
2018
Q2 		$1.97M Buy
+2,693
New +$3.11M 0.01% 1620
2017
Q4 		– Sell
-627
Closed -$226K – 3343
2017
Q3 		$226K Buy
+627
New +$196K ﹤0.01% 2543

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return

John Overdeck's NKTR Position: Q2 2026 in Review

John Overdeck increased its Nektar Therapeutics (NKTR) stake by 29% in Q2 2026, buying an estimated $19.8M and bringing the position to 1,202,004 shares worth $83.9M. The position accounts for 0.06% of the portfolio, ranked #366.

John Overdeck first reported a position in NKTR in Q3 2013 and has held it in 36 quarters since. 239 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • John Overdeck held 1,202,004 shares of Nektar Therapeutics worth $83.9M as of Q2 2026.
  • John Overdeck bought 271,263 Nektar Therapeutics shares in Q2 2026, an estimated $19.8M.
  • Nektar Therapeutics made up 0.06% of John Overdeck's portfolio in Q2 2026, its #366 holding.
  • John Overdeck first reported a position in Nektar Therapeutics in Q3 2013 and has held it in 36 quarters since.
  • 239 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Two Sigma Investments's 13F filing for Q2 2026, filed 14 Aug 2026.